Global Fluphenazine Decanoate Market Overview:
Fluphenazine Decanoate drug is long-acting fluphenazine that is used to treat a variety of psychiatric and mood disorders (chronic schizophrenia). Patients who have benefited from daily doses of short-acting fluphenazine and who may benefit from long-term (maintenance) therapy with less frequent dosing should consider fluphenazine decanoate. This medication is usually pale yellow in color.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Forecast Period | 2024-2030 |
Historical Period | 2018-2023 |
Unit | Value (USD Million) |
Customization Scope | Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility |
Influencing Trend:
Growing R& D Activities across the Globe
Market Growth Drivers:
Increasing Number of People Who Are Suffering From Behavioral Health and Rising Cases of Schizophrenia across the Globe
Challenges:
Stringent Government Rules and Regulations
Restraints:
Side Effects such as Dizziness, Lightheadedness, Nausea
Opportunities:
Emerging Demand from both Developing and Developed Economies and Growth in the Healthcare Sector in Developing Countries
Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Atlantic Laboratories Corporation,Ltd. (Thailand), West Ward Pharmaceuticals (United States), Shanghai Zhongxi Sunve Pharmaceutical (China), Southwest Pharmaceutical (China), Shanghai Harvest Pharmaceutical (China), Par Sterile Products, LLC (United States), Aurobindo Pharma Limited (India) and Fresenius Kabi (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Fluphenazine Decanoate market by 2030. Considering Market by Sales Channel, the sub-segment i.e. Hospital Pharmacy will boost the Fluphenazine Decanoate market. Considering Market by End User, the sub-segment i.e. Children will boost the Fluphenazine Decanoate market.
Latest Market Insights:
In October 2023, Sandoz, a Novartis division, received FDA approval for its generic version of Xepin (Fluphenazine Decanoate) injectable suspension. However, a launch date has not been announced yet.
In April 2023, Sun Pharma launched Fluphenazine Decanoate Injection USP 25mg/ml in the US market. This was a new dosage form of the existing medication, offering a more convenient option for patients.
What Can be Explored with the Fluphenazine Decanoate Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Fluphenazine Decanoate Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Fluphenazine Decanoate
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Fluphenazine Decanoate market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Fluphenazine Decanoate market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Fluphenazine Decanoate Manufacturer, Raw Material Suppliers, Government Regulatory and Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.